Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
Nektar Announces Positive Data on Ovarian Cancer Drug
An experimental drug from Nektar Therapeutics was able to shrink tumors and reduce a cancer biomarker in women with advanced ovarian cancer in a mid-stage study.
Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
ImmunoGen Signs 2nd Licensing Deal with Amgen
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Ligand to Buy Struggling Metabasis
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Melanoma Drug Called a “Breakthrough” After Study
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
New Approval, Clinical Trial for YM Biosciences’ Cancer Drug
The company announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC).
FDA Approves First Maintenance Therapy Drug for Lung Cancer
Two pharmaceutical companies are eager to advance a different approach to treating lung cancer.
